These long-term deleterious effects could result from GLP-1-induced insulin secretion in β cells and hyperinsulinemia, thereby leading to decreased insulin sensitivity and/or augmented priming effects on β cells (22, 23). The gene discussed is INS; the disease is Hyperinsulinemia.